Results 131 to 140 of about 6,220 (295)
Herpes zoster vaccination uptake in rheumatic diseases: persistent implementation gap despite improved uptake. [PDF]
Krasselt M.
europepmc +1 more source
La greffe d'îlots de Langerhans serait pour les patients diabétiques une solution plus physiologique que l'insulinothérapie dont la généralisation sera, malgré son efficacité, limitée par le nombre d'îlots disponibles à partir de pancréas de donneur, et ...
LE MAUFF-QUESTER, Brigitte +1 more
core
A novel engineering strategy that establishes material design principles for incorporating anti‐inflammatory steroids into lipid nanoparticles to reduce LNP‐induced inflammation while retaining mRNA delivery. Results are validated in vitro and in three animal models of inflammation and autoimmunity in vivo.
Ajay S. Thatte +21 more
wiley +1 more source
Large Progressive Right Coronary Artery Aneurysm Secondary to IgG4 Disease. [PDF]
Khan M +5 more
europepmc +1 more source
Propriétés immunosuppressives des cellules souches mésenchymateuses
International ...
Djouad, Farida +6 more
core
An engineered Trojan Mycobacterium, developed via a “peeling‐off and masking‐up” strategy, functions as a powerful splenic myelopoiesis converter. This spleen‐targeted nanomedicine induces trained immunity to reprogram immunosuppressive myeloid reservoirs into antitumoral effectors.
Jin‐Ho Choi +5 more
wiley +1 more source
Incidence of Endophthalmitis after Cataract Surgery in the Setting of Uveitis and Immunosuppressive Therapy within the IRIS® Registry. [PDF]
Ghoraba HH +6 more
europepmc +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
Reassuring evidence on infection risk with dupilumab in atopic dermatitis: Lessons from real-world evidence. [PDF]
van der Gang LF, de Bruin-Weller MS.
europepmc +1 more source

